omniture
logo
Search

Statement by WuXi AppTec Regarding Recent Market Fluctuation

WuXi AppTec
2021-12-16 08:00 2275

SHANGHAI, Dec. 16, 2021 /PRNewswire/ -- Our company's activities continue apace and we remain confident in our platform, which enables our global customers and serves patients around the world. We will provide any new information as warranted and in compliance with applicable laws and regulations.

 

Cision View original content:https://www.prnewswire.com/news-releases/statement-by-wuxi-apptec-regarding-recent-market-fluctuation-301445967.html

Source: WuXi AppTec
Media Room more

WuXi AppTec Revenue Surpassed RMB40 Billion in 2023, and Adjusted Non-IFRS Net Profit Exceeded RMB10 Billion for the First Time

2024-03-18 20:32
1959

WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI™ (lifileucel) for Advanced Melanoma

2024-02-20 21:00
2755
WuXi Advanced Therapies 55,000 square foot commercial non-viral cell therapy manufacturing site, Commerce Center 3 (CC3), located in Philadelphia, PA, United States

WuXi AppTec Triples Peptide Manufacturing Capacity and Launches the New Taixing API Manufacturing Site

2024-01-08 22:00
4526
New API Manufacturing Site at Taixing, Jiangsu, China

WuXi AppTec Named 2023 Global Contract Research, Development and Manufacturing Organization Company of the Year by Frost & Sullivan

2023-11-09 08:00
1533

WuXi AppTec Continued Solid Growth in the First Three Quarters of 2023 on Top of an Exceptionally Strong Year in 2022, with Profit Growth Continuously Exceeding Revenue Growth

2023-10-30 20:01
2060

WuXi AppTec Announced Strong Results of the Second Quarter and First Half of 2023, on Top of an Exceptionally Strong Year in 2022

2023-07-31 18:02
3731
Related News

Brise Pharmaceuticals Raises nearly $20M in Series Pre-A and Pre-A+ Financing

2024-04-23 08:00
696

OSR Holdings and SillaJen have entered into a Memorandum of Understanding to collaboratively pursue the development of innovative therapeutics and enter the U.S. market

2024-04-23 18:37
724

Smartee Showcases Mandibular Repositioning Technology at IDEM Singapore 2024

2024-04-23 16:51
393
Smartee Denti-Technology hosted a specialized event focused on Smartee GS Mandibular Repositioning Technology on April 18th playbtn

HanxBio announces the publication of a research paper in Scientific Reports on preclinical evaluation of Narazaciclib for the treatment of acute myeloid leukemia (AML)

2024-04-23 14:54
579

VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES

2024-04-23 12:45
684

Virtus Fertility Centre Singapore sets up a ReadyBaby Fertility Grant for those facing financial and family planning challenges

2024-04-23 10:59
708
collection